Fubotv earnings beat by $0.10, revenue topped estimates
Viemed Healthcare, Inc. (NASDAQ:VMD), currently trading at $6.59 near its 52-week low of $6.13, announced today that its shareholders approved several significant proposals during the Annual General and Special Meeting held on June 5, 2025. According to InvestingPro analysis, the company maintains a GREAT financial health score of 3.24 out of 5, demonstrating strong operational fundamentals despite recent stock performance. The meeting, which took place in Lafayette, Louisiana, included votes on amendments to the company’s long-term incentive plan and the election of directors.
Shareholders approved an amendment to the 2024 Long Term Incentive Plan (LTIP), which was initially endorsed by the Board of Directors on April 9, 2025. The amendment increases the maximum number of common shares available under the plan, clarifies vesting conditions in the event of a change in control, and establishes a minimum one-year vesting period for all awards. This approval aligns with the company’s strategic goals to enhance its compensation structure.
In the election of directors, all seven nominees were elected to serve until the next annual meeting. The directors elected include Casey Hoyt, W. Todd Zehnder, William Frazier, Randy Dobbs, Nitin Kaushal, Timothy Smokoff, and Sabrina Heltz. The voting results showed strong support, with most nominees receiving over 90% of the votes cast in their favor.
Additionally, shareholders approved the appointment of Ernst & Young LLP as the independent auditors for the fiscal year ending December 31, 2025. The company’s board retains the authority to determine the auditors’ remuneration.
The meeting also included a non-binding advisory vote on executive compensation, known as the "say-on-pay" vote, which received 97.85% approval from shareholders. Furthermore, shareholders agreed that future advisory votes on executive compensation should occur annually.
This information is based on a press release statement filed with the Securities and Exchange Commission (SEC) as part of the company’s 8-K filing. The decisions made during the meeting reflect Viemed Healthcare’s ongoing commitment to aligning its corporate governance practices with shareholder interests. With analyst consensus indicating strong buy recommendations and a moderate debt level, InvestingPro analysis suggests the stock is currently undervalued. For deeper insights into VMD’s valuation and growth prospects, investors can access the comprehensive Pro Research Report, available exclusively to InvestingPro subscribers, along with 6 additional ProTips and over 30 financial metrics.
In other recent news, Viemed Healthcare Inc. reported stronger-than-expected financial results for the fourth quarter of 2024. The company achieved earnings per share of $0.10, surpassing the analyst forecast of $0.09, while revenue reached $60.7 million, exceeding the anticipated $58.5 million. This performance underscores Viemed’s ability to outperform market predictions, reflecting robust growth in its ventilator and sleep therapy businesses. Additionally, Viemed announced plans to acquire Lehan’s Medical (TASE:BLWV) Equipment, an Illinois-based company, for a base purchase price of $26 million, with the transaction expected to close in the third quarter of 2025. This acquisition is part of Viemed’s strategy to expand its market presence and diversify its product offerings. Looking ahead, Viemed projects net revenue between $254 million and $265 million for 2025, alongside an anticipated adjusted EBITDA of $54 million to $58 million. The company plans to focus on organic growth and potential mergers and acquisitions to strengthen its position in the healthcare market. Viemed’s CEO, Casey Hoyt, emphasized the company’s commitment to delivering comprehensive patient-centered care, highlighting its strategic direction and financial stability.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.